Using breakthrough proprietary and patented technology developed by BioHarvest, CannaVcell has announced the first-ever production of Cannabis cells in suspension, with a cannabinoid profile identical to that of the source plant – without the need to grow the plant itself.
The profile of the six cannabinoids (THCA, THC, CBDA, CBD, CBN, CBC) produced by cannabis cells through Biofarming technology. The cannabinoids were analyzed by LC-MS/MS
"This represents the successful completion of the development program that commenced in October of 2018 and aimed to prove the feasibility of BioHarvest’s previously proven technology for the production of Cannabinoids and other Cannabis-derived compounds," the team with the company explains.
"The program was successfully completed 4 months ahead of schedule. The goals for this development stage have been exceeded, as CannaVcell went one step beyond production in liquid media (or suspension) at lab-scale, where it demonstrated fully grown trichomes, and stably produced Cannabis cells and cannabinoids in a small scale bioreactor (Figure 04)."
“It is nothing short of a revolution in the Cannabis world and should be celebrated by the entire industry” said Dr. ZakiRakib co-founder and CEO. He added “we have been waiting for this milestone since we embarked on this journey. We can now check the mark on the feasibility of using BioHarvest’s biofarming technology for the production of Cannabis derived products. In fact, we now shift our attention and resources to the large-scale production process”.
A THCA and CBDA profile produced in cannabis cells grown in liquid media (3B) which is identical to the profile of cannabis flowers (3A). CBDA and THCA were analyzed by HPLC.
BioHarvest expects to complete an initial scale-up process, and reach a commercial production capacity of 2 tons/year by year-end 2020. A significantly larger facility is expected to be completed by year-end 2021. The Bioharvest team has successfully developed industrial scale production processes for other (non-Cannabis) plant cells in the past, and has commercially produced and distributed such products.
“This is a substantial milestone for CannaVcell and a great achievement for BioHarvest’s R&D team. To the best of my knowledge, no other research group or company in the industry has been able to show stable trichome and cannabinoid production through Cannabis cells grown in suspension.
Cannabis cells powder that was produced in a small scale bioreactor.
It appears as if all other research groups that have been focusing on Cannabis cell production have only been able to stably grow trichomes and/or produce cannabinoids in solid media. Doing so in suspension brings CannaVcell and BioHarvest one step closer to commercial scale-up.
I’ve been following CannaVcell’s and BioHarvest’s R&D progress for over a year, and I believe this team has crossed a significant technology threshold. This technology platform can potentially be used for low cost Cannabis derived compound production, for efficient cannabis breeding and secondary metabolite elicitation, as well as for a wide range of R&D applications.” said Mr. Eitan Popper former President and Co-Founder of MedReleaf.
We are delighted to have achieved this milestone” said Dr. Yochi Hagay, CTO of BioHarvest. Dr. Hagay added “when we started the program in October we were tasked to prove the feasibility of the biofarming technology for Cannabis. We exceeded all expectations. We are the first company in the world that has been able to grow cannabis cells that produce six different types of cannabinoids THCA, THC, CBDA, CBD, CBN, CBC, all of which are identical to the cannabinoids produced in the relevant Cannabis flower. I believe this ground breaking technology will usher the cannabis space into a future that enjoys the benefits of low-cost, consistent sources of a complex of cannabinoids at industrial scale with all characteristics that are crucial to global Pharma and CPG companies”.